Business Context and Reporting Period
Company: Delcath Systems, Inc. (DCTH)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: Delcath is an interventional oncology company focused on treating cancers primary or metastatic to the liver. Its lead product, HEPZATO KIT (FDA approved August 2023), is a drug/device combination for uveal melanoma with hepatic metastases. Commercial use began in January 2024. The company also markets CHEMOSAT in Europe.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $7,766 | $495 | $10,905 | $1,092 |
| Gross Profit | $6,247 | $345 | $8,483 | $761 |
| Gross Margin | 80.4% | 69.7% | 77.8% | 69.7% |
| Operating Loss | $(3,912) | $(7,997) | $(14,190) | $(16,322) |
| Net Loss | $(13,741) | $(7,202) | $(24,852) | $(16,202) |
| Cash & Equivalents | $14,782 | $12,646 | $14,782 | $12,646 |
| Short-term Investments | $5,124 | $19,808 | $5,124 | $19,808 |
| Total Debt (Current) | $4,491 | $10,150 | $4,491 | $10,150 |
| Warrant Liability | $15,809 | $5,548 | $15,809 | $5,548 |
Note: Debt figures reflect current liabilities. The Avenue Loan was fully repaid in August 2024, post-period end.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 1,469% QoQ and 900% YTD compared to 2023, driven by the commercial launch of HEPZATO in the U.S. (Q2 2024 HEPZATO revenue: $6.57M) and increased demand for CHEMOSAT in Europe.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose significantly (41% QoQ, 74% YTD) due to commercial launch activities. R&D expenses decreased slightly QoQ but remained elevated YTD.
- Non-Cash Charges: Net loss widened significantly due to a $9.76M non-cash charge from the change in fair value of warrant liabilities in Q2 2024, compared to a gain in the prior year.
- Debt Reduction: The company repaid the remaining principal of the Avenue Loan ($2.5M) in August 2024. Convertible notes payable remain at approximately $4.5M.
- Investments: Short-term investments decreased from $19.8M to $5.1M as the company utilized cash for operations and debt repayment.
Guidance, Outlook, and Risks
- Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern if site activation for HEPZATO is substantially delayed or revenue falls short of expectations. Additional capital may be required within 12 months.
- Capital Commitments: The company estimates $7.8M in commitments for the next 12 months (payables, leases, settlements) and $4.5M in debt principal payments if notes are not converted.
- Future Clinical Trials: Plans to begin studies for HEPZATO in other liver cancers (e.g., colorectal, neuroendocrine) in late 2024 or early 2025.
- Financing: Filed a $150M shelf registration statement (Form S-3) in June 2024. The previous At-The-Market (ATM) facility expired July 1, 2024.
- Risks: Key risks include the uncertainty of reimbursement, competition, supply chain dependencies, and the need for additional equity or debt financing on potentially unfavorable terms.
Investor Verification Checklist
- Revenue Sustainability: Verify the rate of new site activations for HEPZATO and the mix of revenue between HEPZATO and CHEMOSAT to assess growth durability.
- Liquidity Runway: Confirm the timeline for the next capital raise given the "substantial doubt" disclosure and the expiration of the ATM facility.
- Warrant Liability Volatility: Monitor the fair value of the $15.8M warrant liability, as fluctuations significantly impact reported net loss without affecting cash flow.
- Debt Conversion: Track whether holders of the $4.5M convertible notes elect to convert to equity or demand cash repayment.
- Reimbursement Status: Monitor updates on reimbursement approvals for HEPZATO in the U.S. and CHEMOSAT in Europe, which are critical for commercial scaling.